Compare FMBH & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | CMPX |
|---|---|---|
| Founded | 1865 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.4M | 926.7M |
| IPO Year | N/A | N/A |
| Metric | FMBH | CMPX |
|---|---|---|
| Price | $43.25 | $6.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $43.40 | $13.44 |
| AVG Volume (30 Days) | 118.4K | ★ 2.1M |
| Earning Date | 01-29-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.83 | N/A |
| Revenue | ★ $339,295,000.00 | N/A |
| Revenue This Year | $8.91 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | ★ 6.24 | N/A |
| 52 Week Low | $27.58 | $1.33 |
| 52 Week High | $44.85 | $6.88 |
| Indicator | FMBH | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 59.51 |
| Support Level | $42.05 | $6.26 |
| Resistance Level | $44.84 | $6.82 |
| Average True Range (ATR) | 1.16 | 0.36 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 47.51 | 61.45 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.